Merck & Company Inc (MRK)vsOmeros Corporation (OMER)
MRK
Merck & Company Inc
$141.16
-0.63%
HEALTHCARE · Cap: $360.08B
OMER
Omeros Corporation
$17.88
+2.23%
HEALTHCARE · Cap: $1.22B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 173158% more annual revenue ($66.57B vs $38.42M). OMER leads profitability with a 324.9% profit margin vs 4.8%. OMER appears more attractively valued with a PEG of 0.81. OMER earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold36
out of 100
Grade: F
OMER
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$141.16
$57.52 premium
Margin of Safety
+88.1%
Fair Value
$94.46
Current Price
$17.88
$76.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Keeps 325 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Areas to Watch
Trading at 8.3x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 0.3%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : OMER
The strongest argument for OMER centers on Profit Margin, Debt/Equity, PEG Ratio. Profitability is solid with margins at 324.9% and operating margin at 0.3%. Revenue growth of 14.9% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : OMER
The primary concerns for OMER are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while OMER is a mature play — different risk/reward profiles.
OMER carries more volatility with a beta of 2.57 — expect wider price swings.
OMER is growing revenue faster at 14.9% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
OMER scores higher overall (44/100 vs 36/100), backed by strong 324.9% margins and 14.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Omeros Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?